Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.
Andry Van De LouwEric MariotteMichael DarmonAustin CohrsDouglas LeslieElie AzoulayPublished in: PloS one (2021)
Immediate TPE and early rituximab are associated with improved survival in TTP patients. Improved treatments have led to a decline in mortality over time, and alternate outcome variables such as the use of hospital resources or longer term outcomes therefore need to be considered.
Keyphrases
- preterm infants
- end stage renal disease
- ejection fraction
- chronic kidney disease
- healthcare
- diffuse large b cell lymphoma
- metabolic syndrome
- risk factors
- early onset
- emergency department
- cardiovascular events
- acute care
- type diabetes
- adverse drug
- patient reported outcomes
- hodgkin lymphoma
- drug induced
- insulin resistance